Jaguar Health Finalizes Highly Dilutive Series O Preferred Stock Dividend Terms
JAGX sits 49% above its 52-week low of $0.56 on light trading volume (0.2× avg).
Summary
Jaguar Health filed the Certificate of Designation for its Series O Convertible Preferred Stock dividend, revealing highly dilutive floating conversion terms and the potential for pre-funded warrants.
Key Events · Financing and Capital Events · JAGX
-
Certificate of Designation Filed
Jaguar Health filed the Certificate of Designation for its Series O Convertible Preferred Stock on March 2, 2026, formalizing the terms of the special one-time dividend announced on February 18, 2026.
-
Highly Dilutive Conversion Terms
The Series O Preferred Stock features a floating conversion price, where the conversion ratio is determined by dividing a Stated Value of $8.01 by the lower of the common stock's closing price or its 5-day average closing price. This mechanism can lead to significant dilution for common shareholders if the stock price declines.
-
Pre-Funded Warrants for Ownership Limits
If a holder's beneficial ownership would exceed 19.99% upon conversion, the company may issue pre-funded warrants instead of common shares, which are exercisable at $0.001 per share, indicating further potential dilution.
-
No Trading Market for Preferred Stock
There is no established trading market for the Series O Preferred Stock, and the company does not intend to list it on any exchange, limiting liquidity for preferred shareholders.
Analysis · JAGX · Life Sciences
This 8-K filing formalizes the terms of the Series O Convertible Preferred Stock dividend, which was previously announced on February 18, 2026. The Certificate of Designation details a highly dilutive conversion mechanism: the conversion ratio is based on a 'Stated Value' of $8.01 divided by a 'Conversion Price' which is the lower of the common stock's closing price or the 5-day average closing price. This floating conversion price means that if the common stock price declines, more shares will be issued upon conversion, creating a significant overhang and potential for substantial dilution for existing common shareholders. The issuance of pre-funded warrants if beneficial ownership limits are reached further underscores the potential for future dilution. While the company stated the dividend was intended to protect shareholders, the mechanics of this preferred stock introduce considerable risk.
At the time of this filing, JAGX was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.56 to $15.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.